Edward Zamrini

Dr. Edward Zamrini


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMo-Kyung Sin
Mo-Kyung Sin
YCYan Cheng
Yan Cheng
JRJeffrey M. Roseman
Jeffrey M. Roseman
CLCaitlin Latimer
Caitlin Latimer
AAAli Ahmed
Ali Ahmed
EZEdward Zamrini
Edward Zamrini
Alzheimer’s disease (AD) is characterized by cognitive impairment in the presence of cerebral amyloid plaques and neurofibrillary tangles. Less is known about the characteristics and predictors of resilience to cognitive impairment in the presence of neuropathological evidence of AD, the focus of this study. Of 3170 adults age ≥65 years in the National Alzheimer’s Coordinating Center (NACC) brain autopsy cohort, 1373 had evidence of CERAD level moderate to frequent neuritic plaque density and Braak stage V–VI neurofibrillary tangles. Resilience was defined by CDR-SOB and CDR-Global scores of 0–2.5 and 0–0.5, respectively, and non-resilience, CDR-SOB and CDR-Global scores >2.5 and >0.5, respectively. Multivariable logistic regression models were used to examine the independent associations of patient characteristics with resilience. There were 62 participants (4.8%) with resilience. Those with resilience were older (mean age, 88.3 vs. 82.4 years), more likely to be women (61.3% vs. 47.3%) and had a lower prevalence of the APOE-e4 carrier (41.9% vs. 56.2%). They also had a higher prevalence of hypertension, heart failure, atrial fibrillation, diuretic use, beta-blocker use, and APOE-e2 carrier status. Greater age at death, diuretic use, and APOE-e2 were the only characteristics independently associated with higher odds of the AD resilience phenotype (adjusted OR, 1.09; 95% CI, 1.05–1.13; p < 0.01; 2.00 (1.04–3.87), p = 0.04, 2.71 (1.31–5.64), p < 0.01, respectively). The phenotype of resilience to cognitive impairment is uncommon in older adults who have neuropathological evidence of AD.

26 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
EZEdward Zamrini
Edward Zamrini
YCYan Cheng
Yan Cheng
YYYing Yin
Ying Yin
YSYijun Shao
Yijun Shao
HSHelen M Sheriff
Helen M Sheriff
QZQing Zeng
Qing Zeng
Background: Statins are widely prescribed for cardiovascular disease prevention, but their association with Alzheimer’s Disease and Related Dementias (ADRD) remains unclear due to limitations in observational studies. This study emulates a target trial using real‐world data to assess the impact of different statins on ADRD risk. Method: We used the US Veterans Health Administration data to identify patients who initiated a statin between 2002 and 2021. Target trial eligibility was assessed at statin initiation based on criteria including aged 40‐100 years, no ADRD or severe psychiatric conditions, and at least two outpatient visits within two years prior. We studied both fat‐soluble statins (atorvastatin, lovastatin, simvastatin) and water‐soluble (rosuvastatin, pravastatin). To minimize bias, we sampled an equal number of initiators by total cholesterol level (unknown, <200, ≥200 mg/dl) each year for both fat‐ and water‐soluble statins. Both intention‐to‐treat (ITT) and per‐protocol (PP) approaches were used to assess the association between statin initiation and ADRD incidence. Patients were followed up to 20 years, until ADRD diagnosis, death, loss to follow‐up, whichever came first. In the PP approach, patients were also censored if they discontinued the initiated statin for more than 90 days. We fitted Cox regression models to compare the effect of different statins on incident ADRD, adjusting for baseline characteristics including demographics, comorbidities, concurrent medications, vital signs, and laboratory results. Result: A total of 245,633 patients were enrolled in the target trials (32,575 per arm of fat‐soluble statins; 73,954 per arm of water‐soluble statins), with the mean age of 68.8 years; 2.8% females, and 10.5% Blacks. The characteristics for each statin are displayed in Table 1. The mean duration of statin use ranged from 3.3 to 4.6 years, depending on the specific statin (Table 2). Rosuvastatin was associated with the lowest incidence rate of ADRD (Table 2). Adjusted Cox models also indicated that rosuvastatin was associated with a reduced risk of ADRD compared to simvastatin; however, other statins did not show a significant difference from simvastatin (Table 3). Conclusion: Our findings suggest that rosuvastatin may be superior to other statins in reducing the risk of ADRD.